Top stocks in focus on Monday, 10 July 2017
Domestic equity markets are likely to open on a flat note on Monday tracking Nifty futures on the Singapore Stock Exchange (SGX Nifty) and mixed global cues.
SGX Nifty was down 6 points, or 0.06 per cent, at 9,667.50 around 7.55 am (IST), indicating a soft start for NSE Nifty index.
Here is a list of top stocks that are likely to be in focus today:
IDFC: Infra lender IDFC which entered into banking late 2015 and the Piramal Group-backed financial services major Shriram Group on July 8 agreed to merge and create the largest retail-focused bank in the country.
AU Small Finance Bank: Shares of AU Small Finance Bank is going to list on bourses on July 10.
RCom: Reliance CommunicationsBSE 5.27 % (RCom) has presented a long-term debt reduction plan to lenders, which includes sale of real estate, under-sea cable assets and its DTH business, people familiar with the matter said to stagger down debt to reduce 60 per cent by September and 80 per cent by December.
Tata Power: The stressed thermal plants of Tata PowerBSE 1.72 % and Essar Power in Gujarat that run on imported coal are fit for takeover and can be run without technical glitches, state-run power producer NTPCBSE 0.31 % has found in an assessment.
CARE Ratings: CARE Ratings is at the centre of a bidding war with US rating firm Fitch looking to buy into the Mumbai-based rating agency just about 10 days after rival CrisilBSE 2.00 % bought Canara Bank’s 8.9 per cent stake in CARE. Fitch, through its 100 per cent subsidiary India Ratings, has approached some of the large shareholders of CARE, including Life Insurance Corporation of India (LIC) and Franklin Templeton, which collectively hold around 15 per cent stake.
GATI: Express distribution and supply chain company GATI, private equity firm Peepul Capital and TVS Logistics have expressed interest in acquiring Vulcan Express, the logistics arm of beleaguered online marketplace Snapdeal.
Tata Motors: Tata Motors said that the sales of its British luxury unit Jaguar Land Rover (JLR) rose 11 per cent to 51,591 units in June 2017 over June 2016, driven by healthy China market. Jaguar sales grew by 16.4 per cent to 15,343 units in June 2017 over June 2016. Land Rover sales rose 8.9 per cent to 36,248 units in June 2017 over June 2016.
Sun Pharma: Sun Pharmaceutical IndustriesBSE 2.79 % said that the company and one of its wholly-owned subsidiaries have entered into settlements with certain plaintiffs in re Modafinil Antitrust Litigation matter currently pending in the United States District Court for the Eastern District of Pennsylvania. The settlements extend to all claims brought by Apotex Corporation and the Retailer Purchaser Plaintiffs. The settlements remain are confidential.
United Bank ofBSE -0.51 % India: United Bank of IndiaBSE -0.51 % said that it proposes to approve by circulation on July 12,2017, allotment of unsecured Basel III compliant listed Tier-2 bonds, with or without greenshoe option, aggregating upto Rs 500 crore.
Alok Industries: Alok IndustriesBSE 1.71 % said it has been supplied with a copy of the application for resolution proceedings filed by State Bank of IndiaBSE 1.36 %, before the National Company Law Tribunal (NCLT), Ahmedabad on June 29, 2017. The hearing on this matter has been scheduled for July 12, 2017.
UltraTechBSE 0.63 % Cement: Shares of UltraTech Cement turn ex-dividend on Monday, for dividend of Rs 10 per share for the year ended March 2017.
Mindtree: Shares of Mindtree turn ex-dividend today for final dividend of Rs 3 per share for the year ended March 2017.
CeraBSE 0.03 % Sanitaryware: Shares of Cera SanitarywareBSE 0.03 % turn ex-dividend for dividend of Rs 12 per share for the year ended March 2017.
Abbott India: Shares of Abbott IndiaBSE 0.19 % turn ex-dividend for final dividend of Rs 40 per share for the year ended March 2017.
Fortis Healthcare: Reserve Bank has allowed foreign investors to buy more shares in Fortis Healthcare as the company’s board has hiked their investment limit to 74 per cent.
Biocon: Biotechnology major Biocon said that while it has received GMP approval for its biologics drug substance facilities from French Regulator ANSM, its drug product unit will need to be re-inspected.